Unerfüllter Kinderwunsch– Herausforderungen in der Praxis

Sabine Segerer

  1. Van De Kaa DJ. Europe's second demographic transition. Popul Bull 1987; 42(1): 1–59.
  2. American College of O, Gynecologists Committee on Gynecologic P, Practice C. Female age-related fertility decline. Committee Opinion No. 589. Fertil Steril 2014; 101 (3): 633– 4.
  3. Baker TG. A Quantitative and Cytological Study of Germ Cells in Human Ovaries. Proc R Soc Lond B Biol Sci 1963; 158: 417–33.
  4. Block E. Quantitative morphological investigations of the follicular system in women; variations at different ages. Acta Anat (Basel) 1952; 14 (1–2): 108–23. 
  5. Gougeon A, Ecochard R, Thalabard JC. Age-related changes of the population of human ovarian follicles: increase in the disappearance rate of non-growing and early-growing follicles in aging women. Biol Reprod 1994; 50 (3): 653–63.
  6. Wilkosz P, Greggains GD, Tanbo TG, Fedorcsak P. Female reproductive decline is determined by remaining ovarian reserve and age. PLoS One 2014; 9 (10): e108343.
  7. Faddy MJ, Gosden RG. A mathematical model of follicle dynamics in the human ovary. Hum Reprod 1995; 10 (4): 770 –5.
  8. Fleming R, Seifer DB, Frattarelli JL, Ruman J. Assessing ovarian response: antral follicle count versus anti-Mullerian hormone. Reprod Biomed Online 2015; 31 (4): 486–96.
  9. Kalra SK, Ratcliffe SJ, Dokras A. Is the fertile window extended in women with polycystic ovary syndrome? Utilizing the Society for Assisted Reproductive Technology registry to assess the impact of reproductive aging on live-birth rate. Fertil Steril 2013; 100 (1): 208–13.
  10. Franasiak JM, Forman EJ, Hong KH, Werner MD, Upham KM, Treff NR, et al. The nature of aneuploidy with increasing age of the female partner: a review of 15,169 consecutive trophectoderm biopsies evaluated with comprehensive chromosomal screening. Fertil Steril 2014; 101 (3): 656–63 e1.
  11. Pellestor F, Andreo B, Anahory T, Hamamah S. The occurrence of aneuploidy in human: lessons from the cytogenetic studies of human oocytes. Eur J Med Genet 2006; 49 (2): 103–16.
  12. Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ 2000; 320 (7251): 1708–12.
  13. Devesa M, Tur R, Martinez F, Parriego M, Sole M, Rodriguez I, et al. "I will use my own": until what age? Human Reproduction 2015; 30: 70–.
  14. Mensink GB, Schienkiewitz A, Haftenberger M, Lampert T, Ziese T, Scheidt-Nave C. [Overweight and obesity in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56 (5–6): 786–94.
  15. Crujeiras AB, Casanueva FF. Obesity and the reproductive system disorders: epigenetics as a potential bridge. Hum Reprod Update 2015; 21 (2): 249–61.
  16. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89 (6): 2583–9.
  17. Klenov VE, Jungheim ES. Obesity and reproductive function: a review of the evidence. Curr Opin Obstet Gynecol 2014; 26 (6): 455–60.
  18. Heslehurst N, Simpson H, Ells LJ, Rankin J, Wilkinson J, Lang R, et al. The impact of maternal BMI status on pregnancy outcomes with immediate short-term obstetric resource implications: a meta-analysis. Obes Rev 2008; 9 (6): 635–83.
  19. O'Brien TE, Ray JG, Chan WS. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology 2003; 14 (3): 368–74.
  20. Shaw GM, Carmichael SL. Prepregnant obesity and risks of selected birth defects in offspring. Epidemiology 2008; 19 (4): 616–20.
  21. Hammoud AO, Gibson M, Peterson CM, Meikle AW, Carrell DT. Impact of male obesity on infertility: a critical review of the current literature. Fertil Steril 2008; 90 (4): 897–904.
  22. Wei S, Schmidt MD, Dwyer T, Norman RJ, Venn AJ. Obesity and menstrual irregularity: associations with SHBG, testosterone, and insulin. Obesity (Silver Spring) 2009; 17 (5): 1070–6.
  23. Jungheim ES, Moley KH. Current knowledge of obesity's effects in the pre- and periconceptional periods and avenues for future research. Am J Obstet Gynecol 2010; 203 (6): 525 – 30.
  24. Catteau A, Caillon H, Barriere P, Denis MG, Masson D, Freour T. Leptin and its potential interest in assisted reproduction cycles. Hum Reprod Update 2015.
  25. Yu WH, Kimura M, Walczewska A, Karanth S, McCann SM. Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci U S A 1997; 94 (3): 1023–8.
  26. Kitawaki J, Kusuki I, Koshiba H, Tsukamoto K, Honjo H. Leptin directly stimulates aromatase activity in human luteinized granulosa cells. Mol Hum Reprod 1999; 5 (8): 708–13.
  27. Luke B, Brown MB, Stern JE, Missmer SA, Fujimoto VY, Leach R, et al. Female obesity adversely affects assisted reproductive technology (ART) pregnancy and live birth rates. Hum Reprod 2011; 26 (1): 245–52.
  28. Sutton-McDowall ML, Gilchrist RB, Thompson JG. The pivotal role of glucose metabolism in determining oocyte developmental competence. Reproduction 2010; 139 (4): 685–95.
  29. Jungheim ES, Macones GA, Odem RR, Patterson BW, Lanzendorf SE, Ratts VS, et al. Associations between free fatty acids, cumulus oocyte complex morphology and ovarian function during in vitro fertilization. Fertil Steril 2011; 95 (6): 1970–4.
  30. Shah DK, Missmer SA, Berry KF, Racowsky C, Ginsburg ES. Effect of obesity on oocyte and embryo quality in women undergoing in vitro fertilization. Obstet Gynecol 2011; 118 (1): 63–70.
  31. DeUgarte DA, DeUgarte CM, Sahakian V. Surrogate obesity negatively impacts pregnancy rates in third-party reproduction. Fertil Steril 2010; 93 (3): 1008–10.
  32. Bellver J, Ayllon Y, Ferrando M, Melo M, Goyri E, Pellicer A, et al. Female obesity impairs in vitro fertilization outcome without affecting embryo quality. Fertil Steril 2010; 93 (2): 447–54.
  33. Bellver J, Pellicer A, Garcia-Velasco JA, Ballesteros A, Remohi J, Meseguer M. Obesity reduces uterine receptivity: clinical experience from 9,587 first cycles of ovum donation with normal weight donors. Fertil Steril 2013; 100 (4): 1050–8.
  34. Metwally M, Ong KJ, Ledger WL, Li TC. Does high body mass index increase the risk of miscarriage after spontaneous and assisted conception? A meta-analysis of the evidence. Fertil Steril 2008; 90 (3): 714–26.
  35. Kort JD, Winget C, Kim SH, Lathi RB. A retrospective cohort study to evaluate the impact of meaningful weight loss on fertility outcomes in an overweight population with infertility. Fertil Steril 2014; 101 (5): 1400–3.
  36. Wise LA, Rothman KJ, Mikkelsen EM, Sorensen HT, Riis AH, Hatch EE. A prospective cohort study of physical activity and time to pregnancy. Fertil Steril 2012; 97 (5): 1136–42; e1–4.
  37. Sneed ML, Uhler ML, Grotjan HE, Rapisarda JJ, Lederer KJ, Beltsos AN. Body mass index: impact on IVF success appears age-related. Hum Reprod 2008; 23 (8): 1835–9.

Algorithmus-Aspekte zur Myom-Therapie

J. M. Wenderlein  

  1. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Lancet. Oncol. 16, 1061–70 (2015).
  2. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Managing the adnexae at the time of hysterectomy for benign gynaecological disease (Statement, July 2014). www.ranzcog.edu.au/editions/doc_view/2030¬
  3. Parker, W. H. et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstet. Gynecol. 113, 1027–37 (2009).
  4. Jacoby, V. L. et al. Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women’s Health Initiative Observational Study. Arch. Intern. Med. 171, 760–8 (2011). 
  5. Royal Australian & New Zealand College of Obstetricians & Gynaecologists (RANZCOG) and the Australasian CREI Consensus Expert Panel on Trial evidence (ACCEPT) group. Fibroids in infertility Statement, November 2014). www.ranzcog.edu.au/doc/fibroids-in-infertility.html
  6. Donnez, J., Arriagada, P., Donnez, O. & Dolmans, M.-M. Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators. Curr. Opin. Obstet. Gynecol. 27, 422–431 (2015).
  7. Vilos, G. A., Allaire, C., Laberge, P.-Y. & Leyland, N. The Management of Uterine Leiomyomas. J. Obstet. Gynaecol. Canada 37, 157–178 (2015).
  8. Gray, S., Conolly, A., Ma, R., Manzo, E. & Webb, D. The assessment and management of uterine fibroids in primary care. Guidelines.co.uk (2014).
  9. Indication and technics of hysterectomy for benigne diseases. Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/077, March 2015. www.awmf.org/leitlinien/detail/ll/015-070.html.
  10. Donnez, J., Donnez, O. & Dolmans, M. M. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice? Fertil. Steril. 102, 640–648 (2014).
  11. Donnez, J. et al. Long-term medical management of uterine fibroids with ulipristal acetate. Fertil. Steril. 105, 165–176. (2016).
  12. Choosing Wisely: Five Things Physicians and Patients Should Question. An initiative of the ABIM Foundation;www.choosingwisely.org

Clomifen – ein Rückblick: Das Razemat wirkt estrogen und antiestrogen

Prof. M. Breckwoldt

  1. Adashi EY. Clomiphene citrate: Mechanism(s) and site(s) of action. A hypothesis revisited. Fertil Steril 1984; 42: 331-336;
  2. Bettendorf G, Breckwoldt M, Neale, Ch. Die Behandlung der Ovarialinsuffizienz mit Clomiphen. Dtsch Med Wschr 1968; 63: 995-998p;
  3. Breckwoldt M, Bettendorf G. Effects of clomiphene on bio-assays. Fertil Steril 1976, World Congress on Fertil Steril: 163-167;
  4. Greenblatt RB, Barfield WE, Jungck EC, Ray AW. Induction of ovulation with MMRU41. JAMA 1961; 178: 100-104;
  5. Lerner LJ, Holthaus FJ, Thompson CR. A non-steroidal estrogen-antagonist I (p-2-diethylaminoethoxyphenyl). Endocrinology 1958; 63: 295-318. 

Myome bei Frauen mit Kinderwunsch: Was tun?!

Matthias David, Heribert Kentenich

  1. Drayer SM, Catherino WH. Prevalence, morbidity, and current medical management of uterine leiomyomas. Int J Obstet Gynecol 2015; 131: 117-122
  2. Carranza-Mamane B, Havelock J, Hemming R. The management of uterine fibroids in women with otherwise unexplained infertility. JJ Obstet Gynaecol Can 2015; 37: 277–285
  3. Rackow BW, Arici A. Fibroids and in-vitro fertilization: which comes first? Current Opinion in Obstetrics & Gynecology 2005; 17: 225-231 
  4. Zepiridis LI, Grimbizis GF, Tarlatzi BC. Infertility and uterine fibroids. Best Practice & Research Clinical Obstetrics & Gynaecology Dec 2015 doi:10.1016/j.bpobgyn.2015.12.001
  5. Aharoni A, Reiter A, Golan D, Paltiely Y, Sharf M. Patterns of growth of uterine leiomyomas during pregnancy. A prospective longitudinal study. 1988; 95: 510–513
  6. Lam SJ, Best S, Kumar S The impact of fibroid characteristics on pregnancy outcome. Am J Obstet Gynecol. 2014; 211:395.e1-5
  7. Coronado GD, Marshall LM, Schwartz SM. Complications in pregnancy, labor, and delivery with uterine leiomyomas: a population-based study. Obstet Gynecol. 2000; 95:764-769
  8. Klatsky PC, Tran ND, Caughey AB, Fujimoto VY. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol. 2008; 198: 357-366
  9. Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril 2009; 91: 1215-1223
  10. Oliveira FG, Abdelmassih VG, Diamond MP, Dozortsev D, Melo NR, Abdelmassih R. Impact of subserosal and intramural uterine fibroids that do not distort the endometrial cavity on the outcome of in vitro fertilization-intracytoplasmatic sperm injection. Fertil Steril 2004; 81: 582-587
  11. Sunkara SK et al. The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis Hum Reprod 2010; 25: 418-429 
  12. Donnez J, Arriagada P, Donnez O et al. Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators. 2015; 27: 422-431
  13. Bosteels J et al. The effectiveness of hysteroscopy in improving pregnancy rates in subfertile women without other gynaecological symptoms: a systematic review. Hum Reprod Update 2010; 16: 1-11
  14. Shokeir T et al. Submucous myomas and their implications in the pregnancy of patients with otherwise unexplained primary infertility undergoing hysteroscopic myomectomy: a randomized matched control study. Fertil Steril 2010; 94: 724-729
  15. Yoshino O et al. Decreased pregnancy rate is linked to abnormal uterine peristalsis caused by intramural fibroids. Hum Reprod 2010; 25: 2475-2479
  16. Kröncke T, David M. Uterusarterenembolisation (UAE) zur Myombehandlung - Ergebnisse des 5. radiologisch-gynäkologichen Expertentreffens. Fortschr Röntgenstr 2015; 187: 483-485; 
  17. McLucas B, Voorhees WD III, Elliott S. Fertiltiy after uterine artery embolization: a review. Minim Invasiv Ther 2016; 25: 1-7
  18. Rabinovici J et al. Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertil Steril 2010; 93: 199-209
  19. Kröncke T, David M. Magnetresonanz-geführter fokussierter Ultraschall zur Myombehandlung – Ergebnisse des 2. radiologisch-gynäkologischen Expertentreffens. Geburtsh Frauenheilk 2015; 75: 436-438
  20. Ludwig M, Nawroth F, Keck C.  Kinderwunschsprechstunde. Myome. Springer, Berlin Heidelberg S. 69
  21. von Wolff M, Stute P. Gynäkologische Endokrinologie und Reproduktionsmedizin. Das Praxisbuch. Sterilität, Schattauer, Stuttgart 2013. S. 301-311

Möglichkeiten und Grenzen der Moortherapie in der Kinderwunschbehandlung

A.-M. Beer

  1. Beer AM; Goecke C (2000). Balneotherapie und Physiotherapie als primäre und ergänzende Maßnahmen in der Gynäkologie. Gynäkologe, 1:18-27
  2. Beer A-M (2001). Arbeitsgemeinschaft in neuer Verfassung. Frauenarzt, 42(2):212-213
  3. Baatz H (1967) Die gynäkologischen Indikationen für die Moortherapie. Arch Phys Ther 19 (3): 227-234
  4. Naucke W (1988) Stearine und verwandte Verbindungen im Torf (Bestimmungsmethoden). In: Flaig W, Goecke C, Kauffels W (Hrsg) Moortherapie. Grundlagen und Anwendungen. Ueberreuther, Wien Berlin
  5. Lüttig G (2000) Torf ist nicht gleich Torf- Torfart und- beschaffenheit als Basis aller therapeutischen Effekte. In: Beer A-M, Lüttig G, Lukanov J (Hrsg) Moortherapie 2000. BAW, Sofia, S 175-201
  6. Butenandt A, Jacobi H (1933) Über die Darstellung eines kristallisierten pflanzlichen Tokokonins (Thelekynin) und seine Identifizierung mit dem Alpha-Follikelhormon. Z Physiolog Chem 18: 104-112
  7. Munteanu N (1957) Über das Vorkommen östrogener Wirkstoffe in therapeutischen Mooren. Dtsch Med Wochenschr 96
  8. Dahnert E (1963) Über die Östrogene im Torf. Arch Phys Ther 15: 99-106
  9. Sachse J (1974) Die Bestimmung östrogener Isoflavone und Cumöstrol in Klee (Trifolium pratense L. und Trifolium repens L.). J Chromatogr 96: 123-136
  10. Quentin KE (1962) Analyse der Peloide. In: Amelung W, Evers A (Hrsg) Handbuch der Bäder- u. Klimaheilkunde. Schattauer, Stuttgart, S 103–112
  11. Knüvener E, Winterhoff H (1998) Untersuchungen von Cimicifuga-Extrakten im Allen-Doisy-Test. Phytopharmakaforschung 2000, Jahrestagung der Gesellschaft für Phytotherapie, Bonn 27: P06 
  12. Hosemann H (1960) Der Östrogengehalt der organischen Badetorfe und dessen therapeutische Bedeutung. Arch Phys Ther 12: 471-482
  13. Braitenberg H, Velikay L (1963) Ist die therapeutische Östrogenwirkung der Bademoore gesichert? Arch Phys Ther 15: 95-98
  14. Cee K, Luksch F, Brozek B (1966) Zur Frage der perkutanen Östrogenresorption aus dem Bademoor. Z Angew Bäder Klimaheilkd 13: 55-63
  15. Dubiel W (1982) Untersuchungen über Östrogenwirkungen in Badetorfen. Dissertation, Tierärztliche Hochschule Hannover 
  16. Brüller W., Eichler I., Kühnen W (1988) Zu Fragen einer östrogenen Wirkung von Moorbreibädern. Z Phys Med Baln Med Klim 17:84-91
  17. Velikay L (1967) Der biologische Östrogeneffekt während der Moorbehandlung der Ovarialinsuffizienz. Z Angew Bäder Klimaheilkd 14: 49-55
  18. Hildebrandt G, Gutenbrunner Chr (1999) Balneologie. In: Gutenbrunner Chr, Hildebrand G (Hrsg) Handbuch der Balneologie und medizinischen Klimatologie. Springer, Berlin, S 471-474
  19. Beer A M; Lukanov J; Sagorchev P (2000). Der Wirkungsmechanismus von wässerigem Torfextrakt auf die spontane kontraktile Aktivität der glatten Muskulatur. Forsch Komplementärmedizin Klass Naturheilkd., 7(5):237-241
  20. Beer A M; Kovarik R; Münstermann M (1994). Vaginale Mooranwendung bei chronischer Salpingitis. Phys Rehab Kur Med, 4:110-112
  21. Beer AM; Fetaj S; Lange U (2013). Peloidtherapie. Ein Überblick zur Empirie und Evidenz am Beispiel der Heiltorftherapie. Z Rheumatol 72:581-589
  22. Goertz M: Konzept zur wissenschaftlichen Begleitung ausgewählter  Kurbetriebe der Ammergauer Alpen. Vortrag auf dem Internationalen Symposium "Neues aus der Peloidtherapie", Bad Bayersoien 3/ 2014. Abstract publiziert im Abstractband zur Tagung

Fertilitätserhalt im Kindes- und Jugendalter

Ralf Dittrich, Laura Lotz, Inge Hoffmann, Sebastian Findeklee, Matthias W. Beckmann, Patricia Oppelt 

  1. RKI. Krebs in Deutschland 2007/2008. 8.Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin, 2012 2012.
  2. Michaelis J, Kaatsch, P., Kaletsch, U. Jahresbericht 1997 des Deutschen Kinderkrebsregisters, Überlebenszeitanalysen 1998 [cited 2015 14.12.]. Available from: www.kinderkrebsregister.de/typo3temp/secure_downloads/22664/0/8ec3924d2fdf63775d2d0bffa6cf45691264d80f/18_24.pdf.
  3. Kaatsch P, Spix, C. German Childhood Cancer Registry - Annual Report 2015 (1980-2014) Mainz: Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI) at the University Medical Center of the Johannes Gutenberg University Mainz; 2015 [cited 2015 14.12.].
  4. Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer. A pilot survey of survivors' attitudes and experiences. Cancer. 1999;86(4):697-709.
  5. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol. 2005;6(4):209-18.
  6. Borgmann-Staudt A, Rendtorff R, Reinmuth S, Hohmann C, Keil T, Schuster FR, et al. Fertility after allogeneic haematopoietic stem cell transplantation in childhood and adolescence. Bone marrow transplantation. 2012;47(2):271-6.
  7. Reinmuth S, Hohmann C, Rendtorff R, Balcerek M, Holzhausen S, Muller A, et al. Impact of chemotherapy and radiotherapy in childhood on fertility in adulthood: the FeCt-survey of childhood cancer survivors in Germany. J Cancer Res Clin Oncol. 2013;139(12):2071-8.
  8. Wasilewski-Masker K, Seidel KD, Leisenring W, Mertens AC, Shnorhavorian M, Ritenour CW, et al. Male infertility in long-term survivors of pediatric cancer: a report from the childhood cancer survivor study. J Cancer Surviv. 2014;8(3):437-47.
  9. Pfitzer C, Chen CM, Wessel T, Keil T, Sorgel A, Langer T, et al. Dynamics of fertility impairment in childhood brain tumour survivors. J Cancer Res Clin Oncol. 2014;140(10):1759-67.
  10. Bramswig JH, Heimes U, Heiermann E, Schlegel W, Nieschlag E, Schellong G. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer. 1990;65(6):1298-302.
  11. Behringer K, Mueller H, Goergen H, Thielen I, Eibl AD, Stumpf V, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(2):231-9.
  12. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(5):533-8.
  13. Barahmeh S, Al Masri M, Badran O, Masarweh M, El-Ghanem M, Jaradat I, et al. Ovarian transposition before pelvic irradiation: indications and functional outcome. The journal of obstetrics and gynaecology research. 2013;39(11):1533-7.
  14. Gubbala K, Laios A, Gallos I, Pathiraja P, Haldar K, Ind T. Outcomes of ovarian transposition in gynaecological cancers; a systematic review and meta-analysis. Journal of ovarian research. 2014;7:69.
  15. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA, Jr., Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC medicine. 2016;14(1):1.
  16. von Wolff M, Germeyer A, Nawroth F. Fertility preservation for non-medical reasons: controversial, but increasingly common. Deutsches Arzteblatt international. 2015;112(3):27-32.
  17. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol. 2005;23(19):4347-53.
  18. Lotz L, Maktabi A, Hoffmann I, Findeklee S, Beckmann MW, Dittrich R. Ovarian tissue cryopreservation and retransplantation - what do patients think about it? Reproductive biomedicine online. 2016.
  19. Dittrich R, Mueller A, Binder H, Oppelt PG, Renner SP, Goecke T, et al. First retransplantation of cryopreserved ovarian tissue following cancer therapy in Germany. Deutsches Arzteblatt international. 2008;105(15):274-8.
  20. Dittrich R, Lotz L, Keck G, Hoffmann I, Mueller A, Beckmann MW, et al. Live birth after ovarian tissue autotransplantation following overnight transportation before cryopreservation. Fertility and sterility. 2012;97(2):387-90.
  21. Dittrich R, Hackl J, Lotz L, Hoffmann I, Beckmann MW. Pregnancies and live births after 20 transplantations of cryopreserved ovarian tissue in a single center. Fertility and sterility. 2015;103(2):462-8.
  22. Donnez J, Dolmans MM. Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. Journal of assisted reproduction and genetics. 2015;32(8):1167-70.
  23. Anderson RA, Hindmarsh PC, Wallace WH. Induction of puberty by autograft of cryopreserved ovarian tissue in a patient previously treated for Ewing sarcoma. European journal of cancer (Oxford, England : 1990). 2013;49(13):2960-1.
  24. Poirot C, Abirached F, Prades M, Coussieu C, Bernaudin F, Piver P. Induction of puberty by autograft of cryopreserved ovarian tissue. Lancet (London, England). 2012;379(9815):588.
  25. Demeestere I, Simon P, Dedeken L, Moffa F, Tsepelidis S, Brachet C, et al. Live birth after autograft of ovarian tissue cryopreserved during childhood. Human reproduction (Oxford, England). 2015;30(9):2107-9.
  26. Bastings L, Beerendonk CCM, Westphal JR, Massuger LFAG, Kaal SEJ, van Leeuwen FE, et al. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: a systematic review. Human Reproduction Update. 2013;19(5):483-506.
  27. Donnez J, Dolmans MM, Pellicer A, Diaz-Garcia C, Sanchez Serrano M, Schmidt KT, et al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: a review of 60 cases of reimplantation. Fertility and sterility. 2013;99(6):1503-13.
  28. Brannstrom M. Uterus transplantation. Current opinion in organ transplantation. 2015;20(6):621-8.
  29. Jahnukainen K, Ehmcke J, Hou M, Schlatt S. Testicular function and fertility preservation in male cancer patients. Best Pract Res Clin Endocrinol Metab. 2011;25(2):287-302.
  30. Shetty G, Meistrich ML. Hormonal approaches to preservation and restoration of male fertility after cancer treatment. J Natl Cancer Inst Monogr. 2005(34):36-9.
  31. Schlatt S, Kliesch S. Fertilitätsprotektion bei Männern. Gynäkologische Endokrinologie. 2012;10(2):91-7.
  32. Ramasamy R, Lin K, Gosden LV, Rosenwaks Z, Palermo GD, Schlegel PN. High serum FSH levels in men with nonobstructive azoospermia does not affect success of microdissection testicular sperm extraction. Fertility and sterility. 2009;92(2):590-3.

Psychosomatische Aspekte in der Betreuung von Paaren mit unerfülltem Kinderwunsch

Tewes Wischmann, Petra Thorn


  1. Boivin J, Bunting L, Gameiro S. Cassandra’s prophecy: a psychological perspective. Why we need to do more than just tell women. Reprod BioMed Online. 2013;27(1):11-4.
  2. Wippermann C. Gewollte Kinderlosigkeit und aufgeschobener Kinderwunsch. Eine Umfrage in Deutschland. Gynäkol Endokrin. 2016;14(1):49-53.
  3. DIR (Deutsches IVF-Register) Jahrbuch 2014. J Reproduktionsmed Endokrin. 2015;9(6):511-45.
  4. Wischmann T. Einführung Reproduktionsmedizin: Medizinische Grundlagen – Psychosomatik – Psychosoziale Aspekte. München: Reinhardt; 2012. 248 S. p.
  5. Kentenich H, Brähler E, Kowalcek I, Strauß B, Thorn P, Weblus AJ, et al. (Hrsg.). Leitlinie psychosomatisch orientierte Diagnostik und Therapie bei Fertilitätsstörungen. Gießen: Psychosozial-Verlag; 2014.
  6. Wischmann T, Thorn P. Der Mann in der Kinderwunschbehandlung (unter besonderer Berücksichtigung der donogenen Insemination). J Reproduktionsmed Endokrin. 2014;11(3):134-41.
  7. Wallraff D, Thorn P, Wischmann T (Hrsg.). Kinderwunsch. Der Ratgeber des Beratungsnetzwerkes Kinderwunsch Deutschland (BKiD). Stuttgart: Kohlhammer; 2014.
  8. Golombok S. Modern families: parents and children in new family forms. Cambridge: Cambridge University Press; 2015.
  9. Thorn P, Wischmann T. Leitlinien für die psychosoziale Beratung bei Gametenspende. J Reproduktionsmed Endokrinol. 2008;5(3):147-52.
  10. Wischmann T, Thorn P. Psychosoziale Kinderwunschberatung in Deutschland – Status Quo und Erfordernisse für eine bessere Konzeptualisierung, Implementierung und Evaluation. Bericht für das Bundesfamilienministerium. Berlin: BMFSFJ, 2012.
  11. Wischmann T. Paartherapie bei unerfülltem Kinderwunsch. PID. 2014;15(4):76-9.
  12. Stöbel-Richter Y, Thorn P, Kentenich H, Brähler E, Wischmann T. Umfrageergebnisse zum Stellenwert psychosozialer Beratung in reproduktionsmedizinischen Zentren in Deutschland – eine Pilotstudie. J Reproduktionsmed Endokrin. 2011;8(3):416-23.
  13. Wippermann C. Kinderlose Frauen und Männer - Ungewollte oder gewollte Kinderlosigkeit im Lebenslauf und Nutzung von Unterstützungsangeboten. Sozialwissenschaftliche Untersuchung des DELTA-Instituts. Penzberg/Berlin: 2014.
  14. Großmaß R. Hard to reach - Beratung in Zwangskontexten. In: Labonté-Roset C, Hoefert H-W, Cornel H (Hrsg.). Hard to reach - Schwer erreichbare Klienten in der Sozialen Arbeit. Berlin: Schribi-Verlag; 2010. p. 173-85.
  15. Kleinschmidt D, Thorn P, Wischmann T (Hrsg.). Kinderwunsch und professionelle Beratung. Das Handbuch des Beratungsnetzwerkes Kinderwunsch Deutschland (BKiD). Stuttgart: Kohlhammer; 2008.
  16. Wischmann T, Stammer H. Der Traum vom eigenen Kind. Psychologische Hilfen bei unerfülltem Kinderwunsch. 5. Aufl. Stuttgart: Kohlhammer; 2016.
  17. Thorn P. Familiengründung mit Samenspende. Ein Ratgeber zu psychosozialen und rechtlichen Fragen. 2. Aufl. Stuttgart: Kohlhammer; 2010.
  18. Thorn P. Woher manche Babys kommen. Ein Erklärungs- und Aufklärungsbuch für Kinder, die mit medizinischer Unterstützung gezeugt wurden. Mörfelden: FamART Verlag; 2011.
  19. BZgA. Broschürenset “Kinderwunsch" – Ursachen, Behandlung, Hilfen (Broschüren 1-3). 51101 Köln: Bundeszentrale für gesundheitliche Aufklärung (BZgA); 2012.
  20. BZgA. Broschürenset "Kinderwunsch" – Ursachen, Behandlung, Hilfen (Broschüre 4). 51101 Köln: Bundeszentrale für gesundheitliche Aufklärung (BZgA); 2013.
  21. Feibner T, Khaschei K. Hoffnung Kind. Wege zum Wunschkind. Berlin: Stiftung Warentest; 2012.
  22. Stammer H, Verres R, Wischmann T. Paarberatung und -therapie bei unerfülltem Kinderwunsch. Göttingen: Hogrefe; 2004.
  23. Van den Broeck U, Emery M, Wischmann T, Thorn P. Psychosoziale Kinderwunschberatung: Einzel-, Paar- und Gruppeninterventionen. J Reproduktionsmed Endokrin. 2015;12(1):13-8.